SB 202190

CAS : 152121-30-7

Ref. TR-S154495

Informations sur le produit

• Nom: SB 202190
• Synonymes: 4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol, 2,5-cyclohexadien-1-one, 4-[4-(4-fluorophenyl)-1,3-dihydro-5-(4-pyridinyl)-2H-imidazol-2-ylidene]-, 4-(4-Fluorophenyl)-2-(4-Hydroxyphenyl)-5-(4-Pyridyl)Imidazole, 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole, 4-[4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]phenol, 4-[5-(4-Fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol, Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-, Sb 202190, Sb202190, phenol, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-imidazol-2-yl]-

Description

Applications SB 202190 is a DFG inhibitor used in the treatment of colorectal cancer. It is a highly selective, potent inhibitor of p38 MAP kinase. SB-202190 is able to promote proliferation of C6 cells in lower concentration but induced apoptosis in higher levels. Studies show that SB202190 can protect neural function from ischemia/reperfusion injury and regulate the activation of Bcl-2 and Bax protein after ischemia/reperfusion in rat.
References Grossi, V. et al.: Canc. Biol. Ther., 13, 1471 (2012); Chen, Y. et al.: Med. Sci. Mon., 18, BR383 (2012); Horstmann, S. et al.: J. Neurosci. Res., 52, 483 (1998); Zhang, F. et al.: Zhong. Yao. Tong., 18, 512 (2002); Wang, J. et al.: Nanj. Yike Dax. Xue., 29, 840 (2009);

• Marque: TRC

Propriétés chimiques

• Masse moléculaire: 331.34
• Formule: C₂₀H₁₄FN₃O
• Couleur/Forme: Off-White
• InChI: InChI=1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,25H,(H,23,24)
• Code InChI: InChIKey=QHKYPYXTTXKZST-UHFFFAOYSA-N
• SMILES: Oc1ccc(-c2nc(-c3ccncc3)c(-c3ccc(F)cc3)[nH]2)cc1